Sunshine Biopharma, Inc.
SBFM
$2.18
$0.041.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.69% | -8.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.69% | -8.92% | |||
| Cost of Revenue | 6.48% | -12.54% | |||
| Gross Profit | -27.99% | -1.45% | |||
| SG&A Expenses | -23.92% | 34.17% | |||
| Depreciation & Amortization | -22.24% | 3.24% | |||
| Other Operating Expenses | 2.53% | 5.50% | |||
| Total Operating Expenses | -7.34% | 2.88% | |||
| Operating Income | 15.84% | -211.69% | |||
| Income Before Tax | 28.21% | -69.65% | |||
| Income Tax Expenses | -- | 397.23% | |||
| Earnings from Continuing Operations | 41.90% | -142.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.90% | -142.24% | |||
| EBIT | 15.84% | -211.69% | |||
| EBITDA | 15.45% | -257.87% | |||
| EPS Basic | 47.76% | -127.43% | |||
| Normalized Basic EPS | 30.13% | -229.30% | |||
| EPS Diluted | 47.76% | -127.43% | |||
| Normalized Diluted EPS | 30.13% | -229.30% | |||
| Average Basic Shares Outstanding | -90.81% | 6.51% | |||
| Average Diluted Shares Outstanding | -90.81% | 6.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||